Truist raised the firm’s price target on Stryker (SYK) to $413 from $409 and keeps a Hold rating on the shares. The company remains a top-tier MedTech growth name, though its profitability growth is a step behind other premium MedTech large caps, the analyst tells investors in a research note. Truist adds that it is remaining on the sidelines pending a pathway to even greater margin expansion and EPS acceleration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Alphatec likely to benefit as Stryker exits spinal implants, says Lake Street
- Stryker Corp’s Strong Earnings Call Highlights Growth and Strategy
- Stryker price target raised to $427 from $384 at Goldman Sachs
- Stryker price target raised to $402 from $380 at Deutsche Bank
- Stryker price target raised to $435 from $425 at RBC Capital
Questions or Comments about the article? Write to editor@tipranks.com